北京时间5月22日收盘,LYRA市盈率为-10.97,LYRA市值为1亿美元

LYRA简介

LyraTherapeutics,Inc.isaclinical-stagetherapeuticscompanyfocusedonthedevelopmentandcommercializationofnovelintegrateddruganddeliverysolutionsforthelocalizedtreatmentofpatientswithear,noseandthroatdiseases.Thecompany’sproprietarytechnologyplatform,XTreo,isdesignedtopreciselyandconsistentlydelivermedicinesdirectlytotheaffectedtissueforsustainedperiodswithasingleadministration.Thecompany’sinitialproductcandidates,LYR-210andLYR-220,arebioresorbablepolymericmatricesdesignedtobeadministeredinabrief,non-invasive,in-officeprocedureandintendedtodeliveruptosixmonthsofcontinuousdrugtherapytothesinonasalpassagesforthetreatmentofCRS.ThetherapeuticembeddedwithinLYR-210andLYR-220ismometasonefuroate,whichistheactiveingredientinvariousFDA-approveddrugsandhasawell-establishedefficacyandsafetyprofile.CRSisaninflammatorydiseaseoftheparanasalsinuseswhichleadstodebilitatingsymptomsandsignificantmorbiditiesandaffectsapproximately14millionpeopleintheUnitedStates.ThecompanyisadvancingLYR-210asapotentialpreferredalternativetosurgeryinanongoingPhase2clinicaltrialforCRSpatientswhohavefailedmedicalmanagement.InitsPhase1clinicaltrial,LYR-210metitsprimarysafetyendpoint,anditwasobservedthatpatientsgenerallyexperiencedsignificantandrapid,clinicallymeaningfulanddurableimprovementinSNOT-22scores,anestablishedpatientsymptomseverityscale,throughweek25,whichwastheendofthetrial.ThecompanyisalsodevelopingLYR-220foruseinCRSpatientswhohaveanenlargednasalcavityduetosinussurgerybutcontinuetorequiretreatmenttomanageCRSsymptoms.BeyondCRS,thecompanybelievesitsXTreoplatformhaspotentialapplicationsinotherdiseaseareas,whichitisactivelyexploringtofurtherbroadentheplatform’stherapeuticpotential.